Ruitao Lin

Peer-Reviewed Articles

1. Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials. Ann Appl Stat 16(4):2481-2504, 2022. e-Pub 2022. PMID: 36329718.
2. Chi X, Yu Z, Lin R. BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints. Stat Med 41(26):5319-5334, 2022. e-Pub 2022. PMID: 36127794.
3. Ananthakrishnan R, Lin R, He C, Chen Y, Li D, LaValley M. An overview of the BOIN design and its current extensions for novel early-phase oncology trials. Contemp Clin Trials Commun 28:100943, 2022. e-Pub 2022. PMID: 35812822.
4. Chihara D, Lin R, Flowers CR, Finnigan SR, Cordes LM, Fukuda Y, Huang EP, Rubinstein LV, Nastoupil LJ, Ivy SP, Doroshow JH, Takebe N. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400(10351):512-521, 2022. PMID: 35964611.
5. Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med 41(11):1918-1931, 2022. e-Pub 2022. PMID: 35098585.
6. Zhou Y, Lin R, Lee JJ. The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. Pharm Stat 20(6):1183-1199, 2021. e-Pub 2021. PMID: 34008317.
7. Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, Lopez-Mattei JC, Mohan R, Liao Z. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys 111(4):907-916, 2021. e-Pub 2021. PMID: 34302893.
8. Lin R, Chan KG, Shi H. A unified Bayesian framework for exact inference of area under the receiver operating characteristic curve. Stat Methods Med Res 30(10):2269-2287, 2021. e-Pub 2021. PMID: 34468238.
9. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
10. Wen YF, Chen MX, Yin G, Lin R, Zhong YJ, Dong QQ, Wong HM. The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990-2019: a population-based study. J Hematol Oncol 14(1):89, 2021. e-Pub 2021. PMID: 34108026.
11. Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Stat Med 40(11):2626-2649, 2021. e-Pub 2021. PMID: 33650708.
12. Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal 16(1):179-202, 2021. e-Pub 2020. PMID: 34267857.
13. Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials 100:106216, 2021. e-Pub 2020. PMID: 33246098.
14. Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform 5:91-101, 2021. PMID: 33439726.
15. Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc 116(533):322-334, 2021. e-Pub 2020. PMID: 35582047.
16. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. PMID: 33170934.
17. Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics 21(4):807-824, 2020. e-Pub 2019. PMID: 30984972.
18. Park Y, Lin R. Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan. Biometrics 76(2):595-598, 2020. e-Pub 2020. PMID: 32251522.
19. Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials 92:105972, 2020. e-Pub 2020. PMID: 32151751.
20. Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76(1):304-315, 2020. e-Pub 2019. PMID: 31273750.
21. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst 112(1):38-45, 2020. e-Pub 2019. PMID: 30924863.
22. Zheng S, Lin R, Guo J, and Yin G. Testing homogeneity of high-dimensional covariance matrices. Statistica Sinica 30(1), 2020.
23. Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 33283133.
24. Lam CK, Lin R, and Yin G. Non‐parametric overdose control for dose finding in drug combination trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 68(4):1111-1130, 2019.
25. Zhong YJ, Wen YF, Wong HM, Yin G, Lin R, Yang SY. Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. Front Oncol 9:404, 2019. e-Pub 2019. PMID: 31214489.
26. Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat 29(4):648-662, 2019. e-Pub 2019. PMID: 31258039.
27. Lin R. Bayesian optimal interval design with multiple toxicity constraints. Biometrics 74(4):1320-1330, 2018. e-Pub 2018. PMID: 29870069.
28. Lin R, Yin G. Uniformly most powerful Bayesian interval design for phase I dose-finding trials. Pharm Stat 17(6):710-724, 2018. e-Pub 2018. PMID: 30066466.
29. Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24(20):4921-4930, 2018. e-Pub 2018. PMID: 29769209.
30. Lin R, Yin G. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Stat Med 36(26):4106-4120, 2017. e-Pub 2017. PMID: 28786138.
31. Lin R, Yin G. Bayesian optimal interval design for dose finding in drug-combination trials. Stat Methods Med Res 26(5):2155-2167, 2017. e-Pub 2015. PMID: 26178591.
32. Lin R, Yin G. Nonparametric overdose control with late-onset toxicity in phase I clinical trials. Biostatistics 18(1):180-194, 2017. e-Pub 2016. PMID: 27549121.
33. Lin R, Liu Z, Zheng S, Yin G. Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics & Data Analysis 104:10-23, 2016.
34. Lin R, Yin G. Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. The Annals of Applied Statistics 10:2349-2376, 2016.
35. Lin R, Yin G. Bayes factor and posterior probability: Complementary statistical evidence to p-value. Contemp Clin Trials 44:33-35, 2015. e-Pub 2015. PMID: 26212520.
36. Wen YF, Wong HM, Lin R, Yin G, McGrath C. Inter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric Studies. PLoS One 10(8):e0134525, 2015. e-Pub 2015. PMID: 26247212.
37. Yin G, Lin R. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar. Stat Med 34(1):13-7, 2015. PMID: 25492615.
38. Lin R, Yin G, Shi H. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. Biostatistics. e-Pub 2021. PMID: 34296266.

Book Chapters

1. Lin R, Lee JJ. Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. In: Computational and Methodological Statistics and Biostatistics. Springer, 2020.
2. Yuan Y, Lin R. Novel Designs for Early Phase Drug Combination Trials. In: Bayesian Applications in Pharmaceutical Development. Chapman and Hall/CRC, 2019.
3. Lin R, Yin G. Random Walk and Parallel Crossing Bayesian Optimal Interval Design for Dose Finding with Combined Drugs. In: Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017.
4. Lin R, Yin G. Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials. In: Advanced Statistical Methods in Data Science. Springer, Singapore, 2016.
5. Yin G, Lin R. Continual reassessment methods. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.
6. Lin R, Yin G. Adaptive randomization. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.
7. Lin R, Yin G. Sample size re-estimation in adaptively randomized clinical trials with missing data. In: Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. Chapman and Hall/CRC, 2015.

Books (edited and written)

1. Yuan Y, Lin R, Lee JJ. Model-Assisted Bayesian Designs for Dose Finding and Optimization: Methods and Applications. CRC Press, 2022.